Natixis Advisors LLC Buys 54,738 Shares of Elevance Health, Inc. $ELV

Natixis Advisors LLC grew its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 28.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 244,795 shares of the company’s stock after acquiring an additional 54,738 shares during the period. Natixis Advisors LLC’s holdings in Elevance Health were worth $79,099,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the company. Norges Bank acquired a new stake in Elevance Health during the 2nd quarter worth approximately $1,148,379,000. Sanders Capital LLC lifted its holdings in shares of Elevance Health by 24.7% during the second quarter. Sanders Capital LLC now owns 5,825,208 shares of the company’s stock worth $2,265,773,000 after buying an additional 1,152,440 shares in the last quarter. Artisan Partners Limited Partnership boosted its position in shares of Elevance Health by 24.5% in the third quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock valued at $1,478,857,000 after acquiring an additional 901,626 shares during the period. First Eagle Investment Management LLC increased its position in Elevance Health by 25.0% during the third quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company’s stock worth $1,292,029,000 after acquiring an additional 798,457 shares during the period. Finally, Beutel Goodman & Co Ltd. bought a new position in Elevance Health during the second quarter worth about $293,141,000. Institutional investors own 89.24% of the company’s stock.

Elevance Health Trading Up 1.1%

Shares of ELV stock opened at $289.56 on Monday. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $63.91 billion, a P/E ratio of 11.53, a P/E/G ratio of 1.60 and a beta of 0.51. Elevance Health, Inc. has a twelve month low of $273.71 and a twelve month high of $458.75. The stock’s fifty day simple moving average is $344.64 and its 200 day simple moving average is $335.34.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. The firm had revenue of $49.31 billion for the quarter, compared to analyst estimates of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The business’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same period last year, the firm posted $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, sell-side analysts predict that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be given a dividend of $1.72 per share. The ex-dividend date is Tuesday, March 10th. This represents a $6.88 annualized dividend and a yield of 2.4%. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio is 27.23%.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Weiss Ratings cut Elevance Health from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, February 2nd. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $332.00 price objective on shares of Elevance Health in a research note on Thursday, January 29th. Barclays dropped their price objective on Elevance Health from $404.00 to $393.00 and set an “overweight” rating for the company in a report on Friday, January 30th. Sanford C. Bernstein reduced their target price on Elevance Health from $431.00 to $409.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. Finally, Truist Financial decreased their price target on Elevance Health from $400.00 to $390.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. Twelve analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $390.55.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.